newsfilter
← Latest News
Business Wire·

AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit

AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced senior management will be participating in a virtual panel titled